Drug Profile
Watanidipine
Alternative Names: AE 0047; Calbren; GJ 0956; VatanidipineLatest Information Update: 11 Jul 2002
Price :
$50
*
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Antihyperlipidaemics; Antihypertensives; Neuroprotectants
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hypertension; Stroke
Most Recent Events
- 31 Jan 2002 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
- 31 Jan 2002 Discontinued - Preregistration for Hypertension in Japan (unspecified route)
- 01 Oct 2001 Welfide Corporation merged with Mitsubishi-Tokyo Pharmaceuticals to form Mitsubishi Pharma Corporation